CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer.

Yichou WeiChao LinHe LiZhiying XuJieti WangRuochen LiHao LiuHeng ZhangHongyong HeJiejie Xu

Published in: Cancer immunology, immunotherapy : CII (2017)

Intratumoral CXCL13 expression appears as an independent prognostic marker for patients after gastric cancer resection. In addition, CXCL13 expression may serve as a predictive biomarker of response to postoperative adjuvant chemotherapy in these patients.

Keyphrases

end stage renal disease
poor prognosis
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
patients undergoing
patient reported outcomes